Biocon Limited has informed the Exchange regarding a press release dated February 06, 2025, titled "Equillium Inc. and Biocon Limited Announce Positive Data from Phase 2 Study Evaluating Itolizumab in Patients with Moderate to Severe Ulcerative Colitis".